Press release
Familial Mediterranean Fever Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Familial Mediterranean Fever Pipeline. Dive into DelveInsight's comprehensive report today! @ Familial Mediterranean Fever Pipeline Outlook [https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Familial Mediterranean Fever Pipeline Report
* On August 27, 2025, the University of Sao Paulo General Hospital initiated a Phase 4 randomized prospective study involving adult patients with autoimmune rheumatic diseases (ARDs). Participants will receive two intramuscular doses of RZV administered six weeks apart. A control group (CG) consisting of non-immunosuppressed individuals aged greater than or equal to 50 years will also be included, in a ratio of three patients to one control. Patients with ARDs will be randomly assigned to two groups, P1 and P2. Both the CG and P1 groups will receive the vaccine immediately after randomization, on Day 0 (D0) and Day 42 (D42).
* DelveInsight's Familial Mediterranean Fever Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Familial Mediterranean Fever treatment.
* The leading Familial Mediterranean Fever Companies such as Roche, Novartis Pharmaceuticals, R-Pharm International LLC, Soligenix, Amgen, Mitsubishi Tanabe Pharma Corporation, Nobel Pharmaceuticals , and others.
* Promising Familial Mediterranean Fever Pipeline Therapies such as Canakinumab, RPH-104, ACZ885, Dusquetide, AIN457, Apremilast, Infliximab, Apremilast , and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Familial Mediterranean Fever Treatment Drugs [https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Familial Mediterranean Fever Emerging Drugs Profile
* Tocilizumab: Roche
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.
The Familial Mediterranean Fever Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Familial Mediterranean Fever with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Familial Mediterranean Fever Treatment.
* Familial Mediterranean Fever Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Familial Mediterranean Fever Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Familial Mediterranean Fever market
Explore groundbreaking therapies and clinical trials in the Familial Mediterranean Fever Pipeline. Access DelveInsight's detailed report now! @ New Familial Mediterranean Fever Drugs [https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Familial Mediterranean Fever Companies
Roche, Novartis Pharmaceuticals, R-Pharm International LLC, Soligenix, Amgen, Mitsubishi Tanabe Pharma Corporation, Nobel Pharmaceuticals , and others.
Familial Mediterranean Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Subcutaneous
* Intravenous
* Oral
* Parenteral
* Intramuscular
* Molecule Type
Familial Mediterranean Fever Products have been categorized under various Molecule types such as
* Small molecules
* Peptides
* Polymer
* Gene Therapy
* Monoclonal antibodies
* Product Type
Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Familial Mediterranean Fever Market Drivers and Barriers [https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Familial Mediterranean Fever Pipeline Report
* Coverage- Global
* Familial Mediterranean Fever Companies- Roche, Novartis Pharmaceuticals, R-Pharm International LLC, Soligenix, Amgen, Mitsubishi Tanabe Pharma Corporation, Nobel Pharmaceuticals , and others.
* Familial Mediterranean Fever Pipeline Therapies- Canakinumab, RPH-104, ACZ885, Dusquetide, AIN457, Apremilast, Infliximab, Apremilast , and others.
* Familial Mediterranean Fever Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Familial Mediterranean Fever Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight's in-depth pipeline report today! @ Familial Mediterranean Fever Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Familial Mediterranean Fever: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Familial Mediterranean Fever - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Familial Mediterranean Fever Collaboration Deals
* Late Stage Products (Phase III)
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Tocilizumab: Roche
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Drug profiles in the detailed report.....
* Inactive Products
* Familial Mediterranean Fever Key Companies
* Familial Mediterranean Fever Key Products
* Familial Mediterranean Fever- Unmet Needs
* Familial Mediterranean Fever- Market Drivers and Barriers
* Familial Mediterranean Fever- Future Perspectives and Conclusion
* Familial Mediterranean Fever Analyst Views
* Familial Mediterranean Fever Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=familial-mediterranean-fever-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-mediterranean-fever-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Familial Mediterranean Fever Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4167126 • Views: …
More Releases from ABNewswire
Exploring the Future of Precision Finishing: How Metal Sanding Machines Are Rede …
In the fast-evolving world of metal fabrication, achieving flawless finishes and maintaining production efficiency are no longer optional-they are essential. Among the tools leading this transformation is the metal sanding machine , a cornerstone in the pursuit of precision, durability, and surface perfection. At SAMACH Machinery [https://www.samach.cn/collections/metal-sanding-machine], innovation meets craftsmanship, offering a comprehensive range of metal sanding solutions designed for modern industries seeking superior surface quality and operational efficiency.
The Rising…
ResMed AirSense 11 AutoSet Redefines Sleep Apnea Treatment with Intelligent Pres …
Sleep apnea has become a global health concern, affecting millions of people and leading to fatigue, cardiovascular disease, and other chronic health issues. To address this widespread problem, ResMed [https://o2xpress.com/product/airsense11-autoset%e5%85%a8%e8%87%aa%e5%8b%95%e7%9d%a1%e7%9c%a0%e5%91%bc%e5%90%b8%e6%a9%9f-resmed-%e7%91%9e%e6%96%af%e9%82%81/], a world leader in sleep and respiratory care, has introduced the AirSense 11 AutoSet, a groundbreaking innovation that combines cutting-edge technology, intelligent automation, and cloud-based connectivity to revolutionize home sleep therapy.
1. Intelligent Auto-Adjusting Technology: Real-Time Precision for Every Breath
The ResMed…
Ace PR Agency: Over a Decade of Building Author Brands, Visibility, and Global R …
Ace PR Agency celebrates over a decade of success in global PR and digital branding, helping authors and entrepreneurs gain authority through high-impact media features, reputation management, and strategic visibility campaigns across CBS, NBC, FOX, ABC, and major publications.
October 28, 2025 - For more than 10 years, Ace PR Agency has been at the forefront of public relations, digital marketing, and online reputation management, helping authors, entrepreneurs, and businesses transform…
Multi-Functional Design: LST Equipment Breaks Production Barriers, Catering to C …
The global chocolate industry is undergoing a profound transformation, moving beyond traditional mass production toward customization, health consciousness, and ethical sourcing. This shift is placing unprecedented pressure and opportunity on the machinery sector that equips this multi-billion-dollar market. For manufacturers like Chengdu LST Science and Technology Co., Ltd. (LST Machine), understanding and meeting these dynamic needs is key to maintaining market leadership.
Image: https://www.abnewswire.com/upload/2025/10/4de3ebb6292e085fe9d8b52c6b792dec.jpg
A Confluence of Demand: Customization Meets Automation
The industry's…
More Releases for Familial
Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction
Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the…
Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person.
Download the sample report at: https://www.pharmaproff.com/request-sample/1025
A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Familial Amyloid Cardiomyopathy Treatment Market Opportunity Analysis, 2018–20 …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated…
Familial Adenomatous Polyposis Pipeline Therapeutics Development Market Review 2 …
RnRMarketResearch.com adds “Familial Adenomatous Polyposis - Pipeline Review, H1 2017” to its store providing an overview of the Familial Adenomatous Polyposis therapeutic pipeline with comprehensive information on the therapeutic development for Familial Adenomatous Polyposis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews…
Familial Adenomatous Polyposis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.
Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or…
